Cargando...
Safety of switching between rituximab biosimilars in onco-hematology
Comparable clinical efficacy and safety of the reference rituximab (MABTHERA) and its biosimilars has been established in randomized trials. However, safety concerns are often raised when switching from reference to biosimilar products and between different biosimilars. In this prospective observati...
Guardado en:
| Publicado en: | Sci Rep |
|---|---|
| Autores principales: | , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7966361/ https://ncbi.nlm.nih.gov/pubmed/33727667 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-85563-1 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|